UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data

Annals of oncology, 2013-12, Vol.24 (12), p.3028-3034

2013

Volltextzugriff (PDF)

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Gynecologic oncology, 2020-02, Vol.156 (2), p.308-314

2020

Volltextzugriff (PDF)

Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer

Seminars in oncology, 2000-06, Vol.27 (3), p.31-36

2000

Volltextzugriff (PDF)

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study

Annals of oncology, 2018-10, Vol.29, p.viii339-viii339

2018

Volltextzugriff (PDF)

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced?

American journal of obstetrics and gynecology, 1999-09, Vol.181 (3), p.536-541

1999

Volltextzugriff (PDF)

Quality of life and symptoms in longterm survivors with ovarian cancer: It’s still an issue. Expression VI – Carolin meets HANNA – holistic analysis of long-term survival with ovarian cancer: The international NOGGO, ENGOT and GCIG survey

Annals of oncology, 2018-10, Vol.29, p.viii335-viii335

2018

Volltextzugriff (PDF)

Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial

Annals of oncology, 2018-10, Vol.29, p.viii332-viii332

2018

Volltextzugriff (PDF)

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

Gynecologic oncology, 2006-08, Vol.102 (2), p.300-308

2006

Volltextzugriff (PDF)

Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse

Annals of oncology, 2018-10, Vol.29, p.viii333-viii333

2018

Volltextzugriff (PDF)

Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

Annals of oncology, 2018-10, Vol.29, p.viii340-viii341

2018

Volltextzugriff (PDF)

A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Annals of oncology, 2018-10, Vol.29, p.viii344-viii344

2018

Volltextzugriff (PDF)

Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer

Annals of oncology, 2018-10, Vol.29, p.viii344-viii344

2018

Volltextzugriff (PDF)

Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC gynaecological cancer cooperative group study

European journal of cancer (1990), 1999-09, Vol.35 (9), p.1331-1337

1999

Volltextzugriff (PDF)

Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern

Cancer, 1996-10, Vol.78 (8), p.1740-1747

1996

Volltextzugriff (PDF)

Predicting the clinical behavior of ovarian cancer from gene expression profiles

International journal of gynecological cancer, 2006-02, Vol.16 (S1), p.147-151

2006

Volltextzugriff (PDF)

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse

American journal of obstetrics and gynecology, 1993-07, Vol.169 (1), p.40-52

1993

Volltextzugriff (PDF)

Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer

European journal of cancer (1990), 1998-07, Vol.34 (8), p.1175-1180

1998

Volltextzugriff (PDF)

Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer

Cancer, 1992-02, Vol.69 (3), p.741-749

1992

Volltextzugriff (PDF)

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma

Journal of clinical pathology, 1994-10, Vol.47 (10), p.914-919

1994

Volltextzugriff (PDF)

The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG)

Facts, views & vision in ObGyn, 2019-06, Vol.11 (2), p.177-187

2019

Volltextzugriff (PDF)

VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Annals of oncology, 2022-04, Vol.33 (4), p.448-450

2022

Volltextzugriff (PDF)

Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer

European journal of gynaecological oncology, 1998, Vol.19 (5), p.434

1998

Volltextzugriff (PDF)

1064TiPPhase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1028PMirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Are Borderline Tumors of the Ovary Overtreated both Surgically and Systemically? A Review of Four Prospective Randomized Trials Including 253 Patients with Borderline Tumors

Gynecologic oncology, 1993-11, Vol.51 (2), p.236-243

1993

Volltextzugriff (PDF)

1 – 25 von 576

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(554)
Mit Volltextzugriff
(493)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced?

Quality of life and symptoms in longterm survivors with ovarian cancer: It’s still an issue. Expression VI – Carolin meets HANNA – holistic analysis of long-term survival with ovarian cancer: The international NOGGO, ENGOT and GCIG survey

Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse

Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer

Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC gynaecological cancer cooperative group study

Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern

Predicting the clinical behavior of ovarian cancer from gene expression profiles

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse

Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer

Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma

The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG)

VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer

1064TiPPhase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

1028PMirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer

Are Borderline Tumors of the Ovary Overtreated both Surgically and Systemically? A Review of Four Prospective Randomized Trials Including 253 Patients with Borderline Tumors

Suchergebnisse filtern